Encourage • Empower • Leverage
September 2023
NIH Center Grant Bolsters Male Contraceptive Research
February 2023
TDI's First Project Reaches Phase I Clinical Studies
February 2023
On-Demand Male Contraceptive Shows Promise in Preclinical Study
May 2022
Academia, Pharma Team up to Discover New Drugs in Fight Against SARS-CoV-2, Viruses of the Future
November 2020
Caribou Biosciences Licenses fully human anti-CD371 scFvs
March 2022
TDI collaboration leads to anti-ART1 antibody: A potential immune-enhancing cancer treatment
January 2022
Tri-I TDI Relocating to New RU Translational Center
January 2021
Dr Dan Heller Wins TDI Central Protein Database Prize
July 2020
Dr Sara Parsa Wins TDI Central Protein Database Prize
April 2020
TDI Launches Central Protein Database
March 2020
Bridge Medicines Licenses Product from RU Developed with TDI
February 2020
TDI Renews Ties with Takeda Pharmaceuticals and Bridge Medicines
March 2019
Small Molecule Discovered by TDI and Weill Cornell Medicine, Licensed to Bridge Medicine
October 2018
Ablexis, Inc. Licenses TDI-Generated Antibody
June 2018
Peter T. Meinke, PhD, Named New Sanders Director of the TDI
April 2018
TDI Renews Agreement with Schrödinger, Inc. for Access to Drug Discovery Software
March 2018
TDI Licenses First Project to Bridge Medicines
June 2017
TDI's Peter T. Meinke, PhD named "Hero of Chemistry"
May 2017
TDI teams with researchers at The Rockefeller University to develop novel dynein inhibitors
April 2017
January 2017
Ablexis Announces Perpetual License of the AliaMab Mouse to the Tri-I TDI
September 2016
Discovering New Therapeutics through the Power of Philanthropy
June 2016
October 2015
Weill Cornell profiles the Tri-I TDI in the October issue of <em>Weill Cornell Medicine</em>
August 2015
Cyclofluidic Announces Drug Discovery Agreement with the Tri-I TDI
February 2015
September 2014
December 2013
October 2013
Takeda Adds Medicinal Chemistry Heft To NYC Research Partnership
October 2013
Tripling Up for Early-Stage Drug Development
October 2013